ArticleFrontiers in medicine2026
CD163 and the FVIII/FXII ratio identified as novel biomarkers for early sepsis recognition.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plasma proteomic profiling of septic shock and acute pancreatitis identifies shared signatures and disease-specific pathways.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a systemic inflammatory syndrome caused by infection with certain pathogens. It includes sepsis, severe sepsis, and septic shock. In the intensive care unit (ICU), sepsis has a higher mortality rate. Therefore, early identification and management of sepsis can improve outcomes. Objective: All the studies aimed to find out novel markers for early clinical recognition of sepsis. Methods: We retrospectively analyzed 1,245 results of the detection of intrinsic coagulation factors (FVIII, FIX, FXI, and FXII). All the analysis results were visualized by the boxplot, Venn diagram, and circular barplot. After downloading three datasets from the Gene Expression Omnibus (GEO), differentially expressed genes (DEGs), common genes of the three datasets, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis were analyzed and shown. Next, we screened hub genes. Finally, three receiver operating characteristic (ROC) curves were plotted separately for patients of three diseases versus 20 healthy normal subjects. Results: Our analysis of 1,245 clinical specimens revealed that the co-occurrence of elevated FVIII (>150%) and reduced FXII (<50%) was most prevalent in three diseases: cirrhosis ( Conclusion: CD163 and the FVIII/FXII ratio can be used as novel markers for early clinical recognition of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.